Effect of MHSP65-TCL anti-melanoma vaccine on the activity of immunocytes.
- Author:
Bohan DONG
1
;
Guangli DAI
;
Zhilin QI
;
Guang YANG
;
Jun LU
;
Yao ZHANG
Author Information
- Publication Type:Journal Article
- MeSH: Animals; Antigens, CD; metabolism; Antigens, Differentiation, T-Lymphocyte; metabolism; Apoptosis; Bacterial Proteins; administration & dosage; immunology; Cancer Vaccines; Cell Extracts; administration & dosage; immunology; Cell Line, Tumor; Chaperonin 60; administration & dosage; immunology; Female; Interferon-gamma; metabolism; Interleukin-10; metabolism; Lectins, C-Type; metabolism; Melanoma, Experimental; immunology; pathology; Mice; Mice, Inbred C57BL; Random Allocation; Spleen; cytology; immunology; metabolism; Tumor Burden; immunology
- From: Journal of Southern Medical University 2013;33(11):1673-1677
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the therapeutic effect of MHSP65-TCL on melanoma and its effect on the activity of the immunocytes.
METHODSMHSP65-TCL was prepared by mixing MHSP65 with TCL derived from B16 melanoma cell lysate by repeated freezing and thawing. The MHSP65-TCL vaccine was administered in mice bearing B16 melanoma, and the changes in melanoma growth was observed. To investigate the influence of TCL in MHSP65-TCL on the activity of the immunocytes, we co-cultured TCL and mouse spleen cells in vitro, and analyzed CD69 expression on the cells, cell apoptosis, and levels of IL-10 and IFN-γ in the cell culture supernatant.
RESULTSThe MHSP65-TCL vaccine showed an anti-melanoma effect in the tumor-bearing mice. In the in vitro experiment, TCL in MHSP65-TCL strongly stimulated the activation of mouse spleen cells while causing apoptosis in some of the immunocytes and promoting cellular IL-10 secretion, but not IFN-γ.
CONCLUSIONSMHSP65-TCL derived from B16 melanoma cells has an anti-melanoma effect mediated by the activation of immunocytes. TCL in MHSP65-TCL also has immunosuppressive effect on immunocytes possibly due to the presence of suppressive components in TCL, and identifying and eliminating these components may potentially improve the anti-tumor actovoty of MSHP65-TCL vaccine.
